Anticoagulation in Atrial Fibrillation with Mitral Stenosis
Introduction to Anticoagulation
- The American College of Chest Physicians recommends adjusted-dose vitamin K antagonist therapy, such as warfarin, with a target INR of 2.0-3.0 for patients with atrial fibrillation and mitral stenosis, as direct oral anticoagulants are contraindicated in this population 1, 2.
Anticoagulant Choice
- Mitral stenosis is an absolute exclusion criterion for direct oral anticoagulants, such as dabigatran, rivaroxaban, apixaban, and edoxaban, due to lack of safety and efficacy data in this population 1, 2.
- The American College of Chest Physicians explicitly recommends adjusted-dose vitamin K antagonist therapy, such as warfarin, rather than no therapy, aspirin alone, or combination aspirin-clopidogrel for atrial fibrillation patients with mitral stenosis 1.
Target INR and Monitoring
- The target INR for patients with atrial fibrillation and mitral stenosis should be maintained between 2.0-3.0, with evidence suggesting that a target INR of 2.0 is equally effective as higher targets with less bleeding risk 1, 4.
- INR should be checked at least weekly during warfarin initiation and monthly once stable in the therapeutic range, according to guidelines from the American College of Cardiology 2, 5.
Critical Pitfalls to Avoid
- Direct oral anticoagulants should never be used in patients with mitral stenosis, even if the stenosis is mild, due to absolute contraindication based on lack of safety and efficacy data 1, 2.
- Aspirin alone or aspirin-clopidogrel combination should not be substituted for warfarin in high-risk patients, as anticoagulation is vastly superior for stroke prevention 1.